Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Persons Aged ≥18 Years at Risk for Mpox During an Mpox Outbreak: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

PMCID: PMC12176103

PMID: 40531798

DOI: 10.15585/mmwr.mm7422a3

Journal: MMWR. Morbidity and mortality weekly report

Publication Date: 2025-6-19

Authors: Rao AK, Minhaj FS, Carter RJ, Duffy J, Satheshkumar PS, et al.

Key Points

• JYNNEOS is safe and recommended for diverse populations, including those with atopic dermatitis, immunocompromising conditions, and pediatric patients
• Moderate certainty of small disease prevention increase compared to alternative vaccines
• Vaccination recommendations should be individualized based on exposure risk, with careful consideration of patient-specific factors

Summary

This comprehensive review by the Advisory Committee on Immunization Practices (ACIP) evaluates the JYNNEOS vaccine for mpox prevention, providing critical guidance for healthcare professionals during outbreak scenarios. The analysis assessed vaccine effectiveness, safety, and clinical considerations across diverse patient populations, utilizing data from randomized controlled studies and observational research.

The GRADE review determined with moderate certainty that the 2-dose JYNNEOS primary series offers a small increase in disease prevention compared to ACAM2000. The committee unanimously recommended JYNNEOS, noting its safety profile across special populations including immunocompromised individuals, pregnant women, and pediatric patients, with nuanced guidance for specific clinical scenarios such as concurrent COVID-19 vaccination and potential immunoglobulin interactions.